

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent: Anti-SIVmac gp120 Monoclonal (KK8)

Catalog Number: 1403

050001 Lot Number:

Release Category:

Provided: 0.5 ml supernatant fluid

Host: Balb/c splenocyte x NS-O myeloma.

Special

Raised in mice primed with a SIV $_{mac}$ 251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 251 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 31 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 31 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 31 gp160 vaccinia recombinant (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 31 gp160 vaccinia recombination (vAbT253), and boosted with glutaral dehyde-fixed SIV $_{mac}$ 31 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 31 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 31 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 32 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 32 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 32 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 32 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 32 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 42 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 42 gp160 vaccinia recombination (vAbT253) and boosted with glutaral dehyde-fixed SIV $_{mac}$ 42 gp160 vaccinia recombination (vAbT253) and boosted Characteristics:

SIV gp120 V1/V2 region. Specific for SIV_{mac}251 and SIVsm3.

Recommended

Storage:

Keep at 4°C for short term storage and -80°C for long term storage. Avoid

freeze-thaw cycles as reagent degradation may result.

Contributor: Dr. Karen Kent (Produced by CFAR, NIBSC)

Isotype: IgG_{2a}

Kent KA, Gritz L, Stallard G, Cranage MP, Collignon C, Corcoran T, Silvera P, Stott EJ. References:

Production and characterization of monoclonal antibodies to simian immunodeficiency

virus envelope glycoproteins. AIDS 5:829-836, 1991.

Kent KA, Rud E, Cororan T, Powell C, Thiriart C, Collignon C, Stott EJ. Identification of two neutralizing and eight non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses 8:1147-1151,

1992.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 06/12/2018 Page 1 of 2 NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-SIVmac gp120 Monoclonal (KK8) from Dr. Karen Kent." Also include the references cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact NIBSC at the following email address: CFAR@NIBSC.org, before the reagent can be released.

Last Updated

June 12, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 06/12/2018 Page 2 of 2